This announcement is a separate document:
騰盛博藥-B：(1) 建議採納經審核合併財務報表；(2) 建議重選退任董事；(3) 建議續聘核數師；(4) 建議發行及購回股份之一般授權；(5) 建議採納經修訂及重列組織章程大綱及細則；及(6) 股東週年大會通告
BRII-B: (1) PROPOSALS FOR ADOPTION OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS; (2) RE-ELECTION OF RETIRING DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; (4) GENERAL MANDATES TO ISSUE AND BUY-BACK SHARES; (5) PROPOSED ADOPTION OF THE AMENDED AND RESTATED
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.